Health Trials

About this trial

Liver transplantation in children is highly successful with \>80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who have undergone successful transplantation can expect a normal life expectancy or whether there will be a gradual decline in liver function and eventual graft loss. The most common reasons in late graft loss in children are unexplained graft inflammation ("idiopathic" post-transplant hepatitis) and graft fibrosis. PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, has been proved to be a marker of fibrosis in patients with NAFLD. The aim of this study is to explore the role of Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA) in children received liver transplantation.

Eligibility criteria

Qualifiers

Male or female participant must be between 8 weeks and 18 years of age.

Participant is a recipient of a first liver allograft from cadaveric or living donors.

Participant is a single-organ recipient (liver only).

Participants' parent/guardian is capable of understanding the purposes and risks of the study and must sign an informed consent for the study.

Disqualifiers

Participants older than 18 years of age

Pregnant or breastfeeding

Active systemic infections

Receiving any form of solid organ retransplantation

Trial design

Treatments tested in this trial

  • Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)

Treatment groups

1,200 Participants
are divided into 2 treatment groups

Locations

2
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University200127, Shanghai China
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University200127, Shanghai China

Sponsors and collaborators

RenJi Hospital

Lead sponsor

Source ClinicalTrials.gov